Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01370889 · ClinicalTrials.gov registry record · Phase 1

Resveratrol in Postmenopausal Women With High Body Mass Index

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
46
Enrollment target

NCT01370889: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT01370889 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01370889, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target

Study Summary

This pilot phase I trial studies resveratrol in postmenopausal women with high body mass index. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of resveratrol may keep cancer from forming. Studying samples of blood and urine in the laboratory from postmenopausal women who are taking resveratrol may help doctors learn more about the effects of resveratrol on biomarkers.

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG resveratrol

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2011-06
Est. Completion 2012-07
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT01370889

The ClinicalTrials.gov registry entry for NCT01370889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT01370889 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01370889 about?

NCT01370889 is a clinical study titled "Resveratrol in Postmenopausal Women With High Body Mass Index". This pilot phase I trial studies resveratrol in postmenopausal women with high body mass index. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of resveratrol may keep cancer from forming. Studying samples of blood and urine in the laboratory from postmenopausal wome...

What is the current status of trial NCT01370889?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2011-06. Estimated completion is 2012-07.

What interventions are being tested in trial NCT01370889?

The interventions under investigation include: laboratory biomarker analysis (OTHER), resveratrol (DRUG).

Who is sponsoring clinical trial NCT01370889?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.